Velosa Monica, Sergeev Ilia, Sifrim Daniel
Wingate Institute of Neurogastroenterology, Bart and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Neurogastroenterol Motil. 2022 Feb;34(2):e14316. doi: 10.1111/nmo.14316. Epub 2022 Jan 4.
Increased SGB is currently more often recognized not only in patients with belching as a main symptom, but also in patients with reflux like symptoms that are refractory to PPI treatment or patients with reflux hypersensitivity. Detection of increased SGB during analysis of impedance-pHmetry can help to better understand the pathophysiology of symptoms in individual patients and to provide more focused and specific treatment. At the moment, the most efficient treatments for increased SGB are CBT and Speech therapies, pharmacological treatment being less effective and prone to mild secondary effects. In this issue of Neurogastroenterology and Motility, Punkinnen et al demonstrate, in controlled clinical trial, that behavioral therapy was superior to follow-up without intervention in patients with SGB. We present a critical review of the different treatment modalities currently available for patients with pathological SGB.
目前,不仅在以嗳气为主要症状的患者中,而且在对质子泵抑制剂(PPI)治疗无效的反流样症状患者或反流高敏患者中,越来越多地认识到上食管括约肌(SGB)功能增强。在阻抗- pH监测分析过程中检测到SGB功能增强,有助于更好地理解个体患者症状的病理生理学,并提供更有针对性和特异性的治疗。目前,治疗SGB功能增强最有效的方法是认知行为疗法(CBT)和言语疗法,药物治疗效果较差且容易产生轻微的副作用。在本期《神经胃肠病学与动力》杂志中,彭基宁等人在对照临床试验中证明,行为疗法在治疗SGB功能增强的患者方面优于无干预的随访。我们对目前可用于病理性SGB患者的不同治疗方式进行了批判性综述。